About This Eliquis Dosing Guide
This guide provides supplementary information for the Eliquis (apixaban) dose calculator. It outlines the key factors influencing apixaban dosing regimens, such as clinical indication, patient characteristics, renal function, and potential drug interactions, based on FDA-approved prescribing information.
Outputs Explained
The calculator provides a recommended apixaban dosing schedule based on the inputs provided. The primary outputs include:
- Recommended Dose: The specific milligram strength and frequency (e.g., 5 mg orally twice daily).
- Clinical Rationale: A brief note explaining why a particular dose was chosen, especially if it's a reduced dose.
- Calculated Creatinine Clearance (CrCl): For the NVAF indication, the tool calculates CrCl using the Cockcroft-Gault equation to assess renal function, a key factor in dose adjustment.
- Drug Interaction Alerts: Warnings are displayed if the patient is taking concomitant medications known to be strong dual inducers or inhibitors of CYP3A4 and P-gp, which can significantly alter apixaban levels.
How to Use the Calculator
To determine the correct apixaban dose, enter the following patient data into the tool:
- Indication for Use: Select the clinical reason for prescribing apixaban (e.g., NVAF, DVT Treatment).
- Patient Demographics: Enter the patient's age and gender.
- Weight: Provide the patient's body weight in kilograms (kg) or pounds (lbs).
- Serum Creatinine (SCr): Input the most recent SCr value in mg/dL or µmol/L.
- Interacting Medications: Check the appropriate box if the patient is taking a strong dual CYP3A4/P-gp inhibitor (e.g., ketoconazole) or inducer (e.g., rifampin).
Dosing Overview
Stroke Prevention in Nonvalvular Atrial Fibrillation (NVAF)
The standard dose is 5 mg orally twice daily. A dose reduction to 2.5 mg orally twice daily is recommended if a patient meets at least two of the following criteria:
- Age ≥ 80 years
- Body weight ≤ 60 kg
- Serum creatinine ≥ 1.5 mg/dL
Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)
The dosing schedule involves an induction and maintenance phase:
- Induction: 10 mg orally twice daily for the first 7 days.
- Maintenance: 5 mg orally twice daily thereafter.
Prophylaxis of DVT Following Hip or Knee Replacement Surgery
The recommended dose is 2.5 mg orally twice daily. The first dose should be given 12 to 24 hours post-surgery. The duration of therapy is typically 35 days for hip replacement and 12 days for knee replacement.
Reduction in Risk of Recurrent DVT and PE
After at least 6 months of initial treatment, the dose for long-term prevention is 2.5 mg orally twice daily.
Switching Anticoagulants
- From Warfarin to Apixaban: Discontinue warfarin and start apixaban when the International Normalized Ratio (INR) is below 2.0.
- From other DOACs to Apixaban: Start apixaban at the time of the next scheduled dose of the other oral anticoagulant.
- From Apixaban to Warfarin: Discontinue apixaban and begin both a parenteral anticoagulant and warfarin at the time of the next scheduled apixaban dose. Discontinue the parenteral agent once a stable INR of ≥2.0 is achieved.
Missed Dose Instructions
If a dose of Eliquis is missed, the patient should take it as soon as they remember on the same day. They should then resume their regular twice-daily schedule. The dose should not be doubled to make up for a missed one.
Safety Alerts
Premature discontinuation of any oral anticoagulant, including Eliquis, increases the risk of thrombotic events. Epidural or spinal hematomas may occur in patients treated with Eliquis who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis.
Coadministration with strong dual inhibitors of CYP3A4 and P-gp (e.g., ketoconazole, ritonavir) increases apixaban exposure and bleeding risk. Coadministration with strong dual inducers (e.g., rifampin, carbamazepine, St. John's wort) decreases apixaban exposure and increases the risk of stroke. Use should be avoided or adjusted according to prescribing information.
Frequently Asked Questions
Why does the calculator require age, weight, and creatinine for NVAF but not for DVT/PE treatment?
For the NVAF indication, dose reduction is based on a specific set of criteria (age ≥80, weight ≤60kg, SCr ≥1.5 mg/dL). For acute DVT/PE treatment, the dose is standardized and does not require adjustment for these factors according to the FDA label.
What happens if a patient is on a strong inhibitor like ketoconazole?
The calculator will recommend a dose reduction or advise against concomitant use, depending on the indication and the patient's baseline dose, as these drugs significantly increase apixaban levels and bleeding risk.
What is CrCl and why is it important for apixaban dosing?
CrCl (Creatinine Clearance) is an estimate of kidney function. While apixaban's NVAF dose reduction is based on serum creatinine level (≥1.5 mg/dL) as one of three criteria, CrCl is also critical. The FDA label does not recommend use in NVAF patients with CrCl < 15 mL/min.
Is the dose different for hip vs. knee replacement prophylaxis?
No, the dose is the same (2.5 mg twice daily). However, the recommended duration of therapy is different: 35 days for hip replacement and 12 days for knee replacement.
Does this calculator work for patients on hemodialysis?
The calculator reflects FDA labeling, which states that for the NVAF indication, apixaban is not recommended in patients with CrCl < 15 mL/min or on dialysis. Dosing recommendations for patients on dialysis may exist for other indications but require careful clinical judgment.
Why is St. John's wort listed as a potential interaction?
St. John's wort is a strong dual inducer of CYP3A4 and P-gp. It can significantly decrease the concentration of apixaban in the blood, reducing its effectiveness and increasing the risk of stroke or blood clots. Concomitant use should be avoided.
What if a patient meets only one of the three dose reduction criteria for NVAF?
If only one criterion (e.g., age 82) is met, the standard dose of 5 mg twice daily is recommended. The dose is only reduced to 2.5 mg twice daily if at least two of the three criteria are met.
Can this tool be used for patients with mechanical heart valves?
No. Eliquis is not recommended in patients with prosthetic heart valves and has not been studied in this population. This tool is only for the indications listed.
References
- ELIQUIS® (apixaban) tablets, for oral use. U.S. Prescribing Information. Bristol-Myers Squibb Company; Princeton, NJ: Rev March 2021.
- Bristol Myers Squibb and Pfizer. Eliquis (apixaban) for Healthcare Professionals. Accessed [Current Date].
- January CT, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. Circulation. 2019;140:e125–e151.
- U.S. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs. Accessed [Current Date].
I am a Registered Pharmacist under the Pharmacy Act, 1948, and the founder of PharmacyFreak.com. I hold a Bachelor of Pharmacy degree from Rungta College of Pharmaceutical Science and Research. With a strong academic foundation and practical knowledge, I am committed to providing accurate, easy-to-understand content to support pharmacy students and professionals. My aim is to make complex pharmaceutical concepts accessible and useful for real-world application.
Mail- Sachin@pharmacyfreak.com